

DAFTAR PUSTAKA

1. Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J.R., and Clarke, P.A. 1998. Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter “RASCAL” Study. *Journal of the National Cancer Institute*. 90(9): 675 – 83.
2. Anwar, S., Frayling, I.M., Scott, N.A., and Carlson, G.L. 2004. Systemic Review of Genetic Influences on The Prognosis of Colorectal Cancer. *British Journal of Surgery*. 91: 1275 – 1291.
3. Bajaj J, Diaz E, Reya T. Stem cells in cancer initiation and progression. *J Cell Biol*. 2020;219(1):1–12.
4. Barry, E.L., Baron, J.A., Grau, M.V., et al. 2006. K-ras Mutations in Incident Sporadic Colorectal Adenomas. *American Cancer Society*. 106: 1036 – 40.
5. Calcagno, S.R., Colon, S.L., Kreinest, P.A., et al. 2008. Oncogenic K-ras Promotes Early Carcinogenesis in the mouse Proximal Colon. *Int. J Cancer*. 122: 2462 – 2470.
6. Brink, M., de Goeij, A.F., Weijenberg, M.P., et al. 2003. Molecular Epidemiology and Cancer Prevention: K-ras Oncogene Mutation in Sporadic Colorectal Cancer in The Netherlands Cohort Study. *Oxford Journals*. 24(4): 703 – 710.
7. Sa'adah, S. (2018). Sistem Peredaran Darah Manusia. Jakarta
8. Iwasaki, J., Sano, Y., Fu Ki., et al. 2006. Depressed-Type (*O-Hc*) Colorectal Neoplasm in Patients With Family History of First-Degree Relatives with Colorectal Cancer. *World J Gastroenterol*. 21;12(196): 3082 – 7.



9. Añel M., Aurrecoechea, C., Berriman, M., Brestelli, J., Brunk, B. P., Carrington, & Wang, H. (2010). TriTrypDB: a functional genomic resource for the

- Trypanosomatidae. *Nucleic acids research*, 38(suppl_1), D457-D462.
10. Kelompok kerja Adenokarsinoma Kolorektal Indonesia. 2006. : Panduan Pengelolaan Adenokarsinoma Kolorektal Revisi 2006, Jakarta.
 11. Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (review). *Oncol Lett*. 2018;16(1):9–18.
 12. Grady WM, Markowitz SD. The Molecular Pathogenesis of Colorectal Cancer and Its Potential Application to Colorectal Cancer Screening. *Dig Dis Sci*. 2015;60(3):762–72.
 13. Einspahr, J.G., Martinez, M.E., Jiang, R., et al. 2006. Associations of *Ki-ras* Proto-oncogene Mutation and p53 gene Overexpression in Sporadic Colorectal Adenomas with Demographic and Clinicopathologic Characteristics. *Cancer Epidemiology Biomarkers and Prevention. American Association for Cancer Research*. 15:1443 – 1450.
 14. B. Paty, David B. Solit; Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. *Cancer Res* 15 July 2010; 70 (14): 5901–5911. <https://doi.org/10.1158/0008-5472.CAN-10-0192>
 15. Perincheri S, Hui P. KRAS mutation testing in clinical practice. *Expert Rev Mol Diagn*. 2015;15(3):375–84.
 16. Boyle, P., Leon, M.E.. 2002. Epidemiology of Colorectal Cancer. *British Medical Bulletin*. 64: 1-25.
 17. Smith, G., Carey, F.A., Beattie, J., Wilkie, M.J., et al. 2002. Mutation in APC, Kirsten-ras and p53—Alternative Genetic Pathways to Colorectal Cancer. *Pnas* 99(14): 9433 – 9438.



on AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-

- Aguilar J, Kim J. Prognostic and predictive roles of KRAS mutation in colorectal cancer. *Int J Mol Sci.* 2012 Sep 25;13(10):12153-68. doi: 10.3390/ijms131012153. PMID: 23202889; PMCID: PMC3497263.
19. Meng, Mingjing, et al. “The Current Understanding on the Impact of KRAS on Colorectal Cancer.” *Biomedicine & Pharmacotherapy*, vol. 140, Elsevier BV, Aug. 2021, p. 111717. Crossref, doi:10.1016/j.biopha.2021.111717.
20. Cefali, Marco, et al. “Research Progress on KRAS Mutations in Colorectal Cancer.” *Journal of Cancer Metastasis and Treatment*, 1 Jan. 2021, doi:10.20517/2394-4722.2021.61.
21. Arrington, Amanda K. et al. “Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer.” *International Journal of Molecular Sciences* 13.12 (2012): 12153–12168. Available: <http://dx.doi.org/10.3390/ijms131012153>.
22. Koulouridi, Asimina, et al. “Prognostic Value of KRAS Mutations in Colorectal Cancer Patients.” *Cancers*, vol. 3320, no. 14, 7 July 2022, <https://doi.org/10.3390/cancers14143320>.
23. Alghamdi M, Alabdullatif N, Al-Rashoud A, Alotaibi J, Alhussaini N, Elsirawani S, Somily H, Alkhudair N, AlOtaiby M, Ahamed SS, Abd El-Aziz N. KRAS Mutations in Colorectal Cancer: Relationship With Clinicopathological Characteristics and Impact on Clinical Outcomes in Saudi Arabia. *Cureus.* 2022 Mar 30;14(3):e23656. doi: 10.7759/cureus.23656. PMID: 35505757; PMCID: PMC9053648.
24. Baskin, Yasemin, et al. “KRAS Mutation Profile Differences Between Rectosigmoid Localized Adenocarcinomas and Colon Adenocarcinomas.” *Journal of Cancer Metastasis and Treatment*, 1, 1 Aug. 2014, <https://doi.org/10.3978/j.issn.2078-6891.2014.038>.



25. Rimbart, Johan, et al. "Association Between Clinicopathological Characteristics and RAS Mutation in Colorectal Cancer." *Modern Pathology*, vol. 517–526, no. 3, 1 Mar. 2018, <https://doi.org/10.1038/modpathol.2017.119>.
26. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, Wolff HA, Herrmann MK, Beissbarth T, Becker H, Ried T, Ghadimi M. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. *Radiother Oncol.* 2010 Jan;94(1):76-81. doi: 10.1016/j.radonc.2009.10.001. Epub 2009 Nov 11. PMID: 19913317; PMCID: PMC7373270.
27. Alghamdi M, Alabdullatif N, Al-Rashoud A, Alotaibi J, Alhussaini N, Elsirawani S, Somily H, Alkhudair N, AlOtaiby M, Ahamed SS, Abd El-Aziz N. KRAS Mutations in Colorectal Cancer: Relationship With Clinicopathological Characteristics and Impact on Clinical Outcomes in Saudi Arabia. *Cureus.* 2022 Mar 30;14(3):e23656. doi: 10.7759/cureus.23656. PMID: 35505757; PMCID: PMC9053648.
28. Li, Zi-Nan, et al. "BRAF and KRAS Mutations in Metastatic Colorectal Cancer: Future Perspectives for Personalized Therapy." *Gastroenterology Report*, vol. 8, no. 3, Oxford UP (OUP), June 2020, pp. 192–205. Crossref, <https://doi.org/10.1093/gastro/goaa022>.
29. Dinu D, Dobre M, Panaitescu E, Bîrlă R, Iosif C, Hoara P, Caragui A, Boeriu M, Constantinoiu S, Ardeleanu C. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. *J Med Life.* 2014 Oct-Dec;7(4):581-7. PMID: 25713627; PMCID: PMC4316144.



va M, Mihaylova G, Stoyanov GS, Draganova V, Zlatarov A, Kolev N,

Dimitrova E, Conev N, Ivanova D. KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer. Int J Mol Sci. 2023 Aug 13;24(16):12753. doi: 10.3390/ijms241612753. PMID: 37628934; PMCID: PMC10454445.

